15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English Profiles of HBV DNA in a large population of Chinese ...
查看: 615|回复: 0
go

Profiles of HBV DNA in a large population of Chinese patients with chronic hepat [复制链接]

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30441 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

1
发表于 2011-2-7 22:49 |只看该作者 |倒序浏览 |打印
本帖最后由 风雨不动 于 2012-4-14 15:39 编辑

<http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6W7C-50XS692-1&_user=10&_coverDate=02%2F28%2F2011&_rdoc=10&_fmt=high&_orig=browse&_origin=browse&_zone=rslt_list_item&_srch=doc-info>(%23toc%236623%232011%23999459997%232863736%23FL
A%23display%23Volume)&_cdi=6623&_sort=d&_docanchor=&_ct=40&_acct=C000050221&_ver
sion=1&_urlVersion=0&_userid=10&md5=bf33ddcd6d8ce7b008ff452ac565c1ca&searchtype=
a

Journal of Hepatology
Volume 54, Issue 2, February 2011, Pages 195-200

doi:10.1016/j.jhep.2010.06.031 | How to Cite or Link Using DOI
Copyright © 2010 European Association for the Study of the Liver Published by
Elsevier Ireland Ltd.

Research Article
Profiles of HBV DNA in a large population of Chinese patients with chronic
hepatitis B: Implications for antiviral therapy

References and further reading may be available for this article. To view
references and further reading you must purchase this article.

James Funga, Wai-Kay Setoa, Ching-Lung Laia, John Yuena, Danny Ka-Ho Wonga and
Man-Fung Yuen, a,

a Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong
Kong SAR, Hong Kong

Received 19 January 2010;  
revised 6 June 2010;  
accepted 30 June 2010.  
Available online 3 September 2010.

Background & Aims
We determined the virological profile in Chinese chronic hepatitis B (CHB)
subjects and its implications regarding current treatment guidelines. Methods
A total of 1400 treatment-naïve CHB patients had their HBV DNA levels
determined using the Cobas Taqman assay. Patient demographics, HBeAg status, and
liver biochemistry were also recorded. Results The subjects were predominantly
male (62%), had a median age of 45 years, and 301 (22%) were HBeAg-positive. In
subjects aged 25, 26–35, 36–45, 46–55, and >55 years, there was a
decreasing trend of HBV DNA levels of 9.9, 9.3, 8.2, 7.4, and 7.3 log copies/ml,
respectively (p <0.001), in HBeAg-positive subjects, while the pattern was
reversed with HBV DNA levels of 3.7, 4.4, 4.7, 4.9, and 5.2 log copies/ml,
respectively, in HBeAg-negative subjects (p <0.001). In HBeAg-negative subjects,
the proportion of patients with elevated ALT compared to those with normal ALT
was significantly higher in older age groups (p <0.001). In our study
population, by applying the AASLD, EASL, and APASL guidelines, 64%, 99%, and 64%
would be eligible for antiviral therapy, respectively, in HBeAg-positive
patients (with elevated ALT), and 38%, 72%, and 43%, respectively, in
HBeAg-negative patients (with elevated ALT). Up to 54% of patients over the age
of 40 years would be recommended for liver biopsy to determine further
eligibility for treatment. Conclusions For HBeAg-negative CHB, more patients had
elevated ALT and a higher viral load with increasing age. Close monitoring is
recommended in this group so that treatment may be considered. By applying the
current treatment guidelines, a wide discrepancy can be observed in the
proportion of patients eligible for treatment in the absence of histological
data.   
中华肝脏病杂志
54卷,第2期,2011年2月,页195-200

分类号:10.1016/j.jhep.2010.06.031 |如何引用或链接使用分类号
版权所有© 2010年出版的欧洲肝脏研究协会
埃尔塞维尔爱尔兰有限公司

研究论文
乙肝病毒DNA图谱在一个中国人口众多患者的慢性
乙型肝炎:抗病毒治疗的启示

参考文献和可能提供进一步阅读本文。要查看
参考和进一步阅读你必须购买这篇文章。

詹姆斯Funga,伟凯Setoa,李金龙拉美一体化协会,约翰Yuena,丹尼家和何旺厄
文凤园,一,

一个医学部,香港玛丽医院大学,香港
香港特区政府,香港

收到2010年1月19日;
经修订的2010年6月6日;
接受二〇一〇年六月三十日。
可在线2010年9月3日。

背景和目的
我们决心在中国慢性乙型肝炎(CHB)的病毒学专页
学科及其影响就当前治疗指南。方法
一个1400治疗初治慢性乙型肝炎患者乙肝病毒DNA水平有其
确定使用的COBAS荧光定量检测。病人的人口统计资料,HBeAg状态,以及
肝功能也被记录下来。结果受试者主要
男性(62%),有一个45岁的年龄中位数,和301(22%)为HBeAg阳性。在
25岁,26-35,36-45科目,46-55,和“> 55岁,有一个
降低乙肝病毒DNA的9.9,9.3,8.2,7.4和7.3 log拷贝/ mL水平的趋势,
(P均“0.001),e抗原阳性者,而格局
与HBV DNA水平扭转为3.7,4.4,4.7,4.9和5.2 log拷贝/毫升,
分别在HBeAg阴性组(P“0.001)。 e抗原阴性者,
与ALT升高的患者的比例相比,ALT正常者
显着高于年龄组(P“0.001)。在我们的研究
人口,通过应用美国肝病学会,欧洲肝病学会和APASL指南,64%,99%和64%
有资格的抗病毒治疗,分别在e抗原阳性
病患(ALT升高),38%,72%和43%,分别在
e抗原阴性病患(ALT升高)。高达54%以上的患者的年龄
40年便被推荐为肝活检以确定进一步
资格接受治疗。对于HBeAg阴性慢性乙型肝炎的结论,更多的患者
ALT升高和较高的病毒载量随着年龄的增加。密切监测
建议在这因此治疗组可以考虑。通过应用
目前的治疗准则,一个很大的差距,可观察到
接受治疗的患者比例资格的情况下,在组织学
数据。                       



(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-5-19 04:58 , Processed in 0.013124 second(s), 11 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.